Advertisement

Canada begins review of Oxford coronavirus vaccine candidate

Click to play video 'Coronavirus: Trudeau announces agreement with AstraZeneca for 20 million vaccine doses if trials successful' Coronavirus: Trudeau announces agreement with AstraZeneca for 20 million vaccine doses if trials successful
WATCH ABOVE: Trudeau announces agreement with Oxford-AstraZeneca for 20 million coronavirus vaccine doses if trials successful

OTTAWA – Canada launched on Friday a real-time review of data from AstraZeneca and Oxford University’s potential COVID-19 vaccine, becoming the latest country to speed up its approval process.

Read more: Canada signs deal to obtain 20M doses of Oxford coronavirus vaccine candidate

As the battle against the coronavirus pandemic intensifies, with infections and deaths still rising, Canada‘s health ministry said it had received its first submission for authorisation for the vaccine on Thursday.

The aim of a rolling review is to accelerate the process and last month, Canada‘s health minister Patty Hajdu signed an order allowing companies developing vaccines to submit safety and efficacy data and information as they become available.

Click to play video 'Canada signs new coronavirus vaccine deals' Canada signs new coronavirus vaccine deals
Canada signs new coronavirus vaccine deals

 

Story continues below advertisement

The European Union’s health regulator on Thursday also started a rolling review of the first batch of data for the potential vaccine being worked on by AstraZeneca.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

The British drugmaker and Oxford University did not immediately respond to requests for comment.

Read more: Should the COVID-19 vaccine be mandatory? New poll suggests Canadians are divided

The Canadian ministry will not decide whether to authorize this or any other vaccine until it has received the necessary evidence to support its safety, efficacy and quality, it said

It is also in talks with several vaccine manufacturers and said any company can apply to use the rolling review process.

Last week, Canada agreed to buy up to 20 million doses of the vaccine candidate, one of several deals it has signed to secure around 300 million potential shots as the global death toll from coronavirus exceeds 1 million.

Click to play video 'Coronavirus: AstraZeneca pauses COVID-19 vaccine trial after participant gets unexplained illness' Coronavirus: AstraZeneca pauses COVID-19 vaccine trial after participant gets unexplained illness
Coronavirus: AstraZeneca pauses COVID-19 vaccine trial after participant gets unexplained illness

Called AZD1222 or ChAdOx1 nCoV-19, the AstraZeneca vaccine is seen as leading the race to inoculate people against COVID-19. Other vaccine hopefuls in advanced stages include those from Pfizer, Moderna and Sinovac.

Story continues below advertisement

— Reporting by Steve Scherer in Ottawa; additional reporting by Pushkala Aripaka in Bengaluru and Alistair Smout in London; Writing by Josephine Mason in London Editing by Chizu Nomiyama, Mark Potter and Alexander Smith